Role of Proton Pump Inhibitors in Cardiac Patients: Guideline Recommendations Versus Practical Approach
Open Access
- 8 June 2024
- journal article
- review article
- Published by SAGE Publications in Indian Journal of Clinical Cardiology
- Vol. 5 (3) , 248-257
Abstract
Dual-antiplatelet therapy (DAPT) is a cornerstone treatment for patients diagnosed with acute coronary syndrome (ACS) and coronary artery disease (CAD). Although DAPT effectively reduces the occurrence of thrombotic events, it also substantially increases the likelihood of gastrointestinal (GI) bleeding. Proton pump inhibitors (PPIs) are essential for mitigating the GI bleeding risk, yet concerns persist regarding their prolonged use and potential adverse effects. Apart from rabeprazole, PPIs share the hepatic metabolism pathway with clopidogrel, resulting in unfavorable cardiovascular outcomes. The pairing of rabeprazole with clopidogrel emerges as a prudent recommendation, displaying superior efficacy in mitigating major adverse cardiovascular events (MACE) when juxtaposed with other PPIs. This narrative review underscores the complexity of managing PPIs in cardiac patients and emphasizes the importance of tailored approaches based on emerging evidence while providing valuable insights to clinicians navigating this challenging therapeutic landscape.Keywords
This publication has 58 references indexed in Scilit:
- Cardiovascular Compatibility of Proton Pump Inhibitors: Practice RecommendationsCardiology and Therapy, 2023
- Optimal antiplatelet therapy for prevention of gastrointestinal injury evaluated by ANKON magnetically controlled capsule endoscopy: Rationale and design of the OPT-PEACE trialAmerican Heart Journal, 2020
- Meta-Analysis of Efficacy and Safety of Proton Pump Inhibitors with Dual Antiplatelet Therapy for Coronary Artery DiseaseCardiovascular Revascularization Medicine, 2019
- Proton pump inhibitors: Review of reported risks and controversiesLaryngoscope Investigative Otolaryngology, 2018
- Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT TrialThe American Journal of Medicine, 2016
- Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteersArchives of Cardiovascular Diseases, 2013
- Proton Pump Inhibitors and Risk of 1-Year Mortality and Rehospitalization in Older Patients Discharged From Acute Care HospitalsJAMA Internal Medicine, 2013
- Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrelBiopharmaceutics & Drug Disposition, 2012
- Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary SyndromeJAMA, 2009
- Relative potency of proton-pump inhibitors—comparison of effects on intragastric pHEuropean Journal of Clinical Pharmacology, 2008